ArTS Archivio della ricerca di Trieste

SAVA, GIANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.153
EU - Europa 9.299
AS - Asia 2.024
SA - Sud America 42
AF - Africa 34
Continente sconosciuto - Info sul continente non disponibili 30
OC - Oceania 11
Totale 29.593
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.109
UA - Ucraina 1.928
SE - Svezia 1.887
DE - Germania 1.129
PL - Polonia 1.120
CN - Cina 1.003
IT - Italia 950
FI - Finlandia 580
HK - Hong Kong 495
GB - Regno Unito 465
TR - Turchia 342
BG - Bulgaria 305
RU - Federazione Russa 298
IE - Irlanda 294
FR - Francia 146
CH - Svizzera 53
IN - India 39
CA - Canada 33
KR - Corea 31
EU - Europa 30
BE - Belgio 28
SG - Singapore 28
SN - Senegal 23
BR - Brasile 19
NL - Olanda 19
VN - Vietnam 18
RO - Romania 17
SA - Arabia Saudita 12
PT - Portogallo 11
TH - Thailandia 11
AT - Austria 10
CL - Cile 10
CZ - Repubblica Ceca 10
RS - Serbia 10
ID - Indonesia 9
DK - Danimarca 7
ES - Italia 7
MX - Messico 7
MY - Malesia 7
AU - Australia 6
EG - Egitto 6
GR - Grecia 6
HR - Croazia 6
IR - Iran 6
AR - Argentina 5
HU - Ungheria 5
JP - Giappone 5
NZ - Nuova Zelanda 5
GE - Georgia 4
VE - Venezuela 3
BO - Bolivia 2
CO - Colombia 2
IL - Israele 2
LB - Libano 2
MA - Marocco 2
MD - Moldavia 2
PK - Pakistan 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
DO - Repubblica Dominicana 1
FK - Isole Falkland (Malvinas) 1
GT - Guatemala 1
HN - Honduras 1
JO - Giordania 1
KE - Kenya 1
LU - Lussemburgo 1
MN - Mongolia 1
NI - Nicaragua 1
NO - Norvegia 1
SI - Slovenia 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 29.593
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.486
Ann Arbor 2.405
Fairfield 1.905
Houston 1.682
Jacksonville 1.663
Chandler 1.277
Wilmington 1.108
Warsaw 1.104
Ashburn 1.021
Seattle 828
Cambridge 647
Princeton 582
Hong Kong 487
Beijing 366
Sofia 305
Dublin 291
Izmir 281
Dearborn 217
Boardman 187
Trieste 163
San Diego 138
Milan 109
Düsseldorf 81
Chicago 66
Hefei 61
Falls Church 55
Verona 53
Kocaeli 51
Norwalk 48
Redwood City 48
Kunming 44
Bern 43
Buffalo 42
Bremen 41
Nanjing 40
Mestre 39
Phoenix 34
Des Moines 32
Jinan 32
Guangzhou 30
Brussels 26
Dakar 23
Seoul 23
Columbus 22
Helsinki 22
Shanghai 22
Andover 19
Fuzhou 17
Nanchang 16
Auburn Hills 15
Ottawa 15
Redmond 15
Shenyang 15
Dong Ket 14
Hebei 14
Hangzhou 13
Los Angeles 13
Zhengzhou 13
Fremont 11
New York 11
Chengdu 10
Mountain View 10
Singapore 10
Poplar 9
Chongqing 8
Indiana 8
Vienna 8
Baotou 7
Changsha 7
Costa Mesa 7
Dallas 7
Grafing 7
North Bergen 7
Tappahannock 7
Wuhan 7
Xian 7
Brno 6
Chaoyang 6
Chennai 6
Lisbon 6
London 6
Polska 6
Pune 6
Riyadh 6
São Paulo 6
Tianjin 6
Washington 6
Wenzhou 6
Al Kharj 5
Amsterdam 5
Athens 5
Atlanta 5
Cardiff 5
Dongguan 5
Jiaxing 5
Munich 5
Nanning 5
Padova 5
Palermo 5
Paris 5
Totale 20.689
Salva come PNG Salva come JPEG
Nome #
Effects of Two Fullerene Derivatives on Monocytes and Macrophages 397
Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin 305
Pharmacological activities of ruthenium complexes related to their NO scavenging properties 287
Identification and Characterization of a Novel Family of Cysteine-Rich Peptides (MgCRP-I) from Mytilus galloprovincialis 278
Chemical and Molecular Approach to Tumor Metastases 265
The differential distribution of RAPTA-T in non-invasive and invasive breast cancer cells correlates with its anti-invasive and anti-metastatic effects 232
A Cationic [60] Fullerene Derivative Reduces Invasion and Migration of HT-29 CRC Cells in Vitro at Dose Free of Significant Effects on Cell Survival 214
Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A 204
New salts of anionic complexes of Ru(III) as antimetastatic and antineoplastic agents. 194
Sulfoxide ruthenium complexes: non toxic tools for the selective treatment of solid tumour metastases. 177
The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure 175
Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use. 172
Reduction of lung metastases by Na[trans-RuCl4(DMSO)Im] is not coupled with the induction of chemical xenogenization 165
Efficacy of 5-FU combined to Na[trans-RuCl4(DMSO)(Im)], a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma 164
A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results 160
Tumor inhibition and effects on host survival time by rutheniumIII andrhodiumIII complexes with dimethylsulphoxide ligands. 159
Chemical, biological and antitumor properties of ruthenium(II) complexes with dimethylsulfoxide 158
Ruthenium(III) complexes as antineoplastic agents. 154
Response of MCa mammary carcinoma to cisplatin and to Na[trans-RuCl4(DMSO)(Im)]. 153
Investigation on the oxidative N-demethylation of aryltriazenes in vitro 153
Hydrophilic polymer coated monodispersed Fe3O4 nanostructures and their cytotoxicity 153
Effects of lysozyme on spleen and lungs in mice with Lewis lung carcinoma 151
Reconsidering clinical pharmacology frameworks as a necessary strategy for improving the health care of patients: a systematic review 149
Complessi trans di rutenio come agenti antineoplastici 148
Antitumor and antimetastatic effects of benzenoid triazenes in mice bearing Lewis lung carcinoma. 148
Antiinflammatory action of hydrosoluble dimethyltriazenes on the carrageenin-induced edema in guinea pigs 148
Complessi dicarbossilati del rutenio(II) e loro impiego come antitumorali 146
Rhodium(III) analogues of antitumour-active ruthenium(III) compounds: the crystal structure of [ImH][trans-RhCl4(Im)2] (Im= imidazole) 146
Antitumor action of mer-trichlorobis(dimethyl sulfoxide)aminoruthenium(III) (BBR2382) in mice bearing Lewis lung carcinoma 145
Na[trans-RuCl4(DMSO)(Im)]*2DMSO - antimetastatic ruthenium agent 143
Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichloro-diamminoplatinum(II) in mice bearing Lewis lung carcinoma 143
Effects of antimetastatic, antiinvasive and cytotoxic agents on the growth and spread of transplantable leukemias in mice. 143
RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A 143
Biochemical and biological characteristics of leucocyte proteinase inhibitors. 142
Effects of trans-RuCl2 (DMSO)4 on B16 melanoma in mice. 141
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes 141
trans-Ru(II)dimethylsulfoxides: antineoplastic action on mouse tumors 141
Human recombinant lysozyme downregulates advanced glycan endproduct-induced interleukin-6 production and release in an in vitro model of human proximal tubular epithelial cells 141
The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions 141
Ruthenium-Porphyrin Conjugates with Cytotoxic and Phototoxic Antitumor Activity 138
Pharmacological aspects and therapeutic applications of lysozymes 138
Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties 138
Ruthenium complexes can target determinants of tumour malignancy 136
Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice 136
Reduction of B16 melanoma metastases by oral administration of egg-white lysozyme 135
Effects of endotoxin in mice bearing solid metastasizing tumors and treated with lysozyme hydrochloride 135
Can peptides be orally-delivered in crustaceans? The case study of the Crustacean Hyperglycaemic Hormone in Procambarus clarkii 135
In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model 135
Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell Invasion. 134
Antitumor properties of ruthenium(II)-dimethylsulfoxide complexes in the Lewis lung carcinoma system 134
Influence of the anionic ligands on the anticancer activity of Ru(II)-dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors 134
Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy 133
The development of tumor-inhibiting ruthenium dimethylsulfoxide complexes 133
Antimetastatic effects and tumor proteinase inhibition by spleen intracellular inhibitors of neutral proteinases. 133
Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms 133
Antimetastatic action of the prostacyclin analog Iloprost in the mouse 133
Metal-Based Inhibition of Poly(ADP-ribose) Polymerase - The Guardian Angel of DNA 132
Lysozyme induced recovery of the response to ConA on mononuclear cells harvested from mice bearing MCa mammary carcinoma 132
Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an antimetastatic ruthenium complex 131
Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. 130
Methodologic problems encountered in the assay of proteinases in Lewis lung carcinoma, a mouse metastasizing tumor. 130
null 130
Rhodium(III) analogs of antitumor active ruthenium(III) compounds. The crystal structure of [ImH][trans-RhCl4(Im)2] (Im = imidazole) 129
Antimetastatic effects of N-diazoacetyl-glycine derivatives in C57BL mice. 128
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs 128
Evidence for host-mediated antitumor effects of lysozyme in mice bearing MCa mammary carcinoma 128
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy 128
Antileukemic action of RuCl2(DMSO)4 isomers and prevention of brain involvement on P388 leukemia and on P388/DDP subline 127
Tumour metastatic potential after treatment with selective antimetastatic drugs 127
Neutral proteinase inhibitors and antimetastatic effects in mice. 126
Effects of p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt on leukemic infiltration of brain and liver in mice bearing P388 leukemia. 126
Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity 126
Free exchange across cells,and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A(imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate)ON KB Tumor cells. 125
Mechanism of the antimetastatic action of N-diazoacetylglycinamide in mice bearing Lewis lung carcinoma. 125
Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition 124
Ruthenium-sulfoxide complexes with a specific antimetastatic activity 124
Antitumor effects of GANU and other nitrosourea derivatives against transplantable leukemias and solid tumors in mice. 124
Profiling the molecular mechanism of fullerene cytotoxicity on tumor cells by RNA-seq 124
Effects of L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine on the antitumor action of cyclophosphamide, 5-FU, cisplatin and dacarbazine on advanced carcinomas of the mouse 123
Microencapsulation of Bioactive Principles with an Airless Spray-Gun Suitable for Processing High Viscous Solutions 123
Antineoplastic effects of mer-RuCl3(DMSO)2(NH3) against murine tumors: comparison with cisplatin and with ImH[RuIm2Cl4]. 122
Metal complexes of platinum group: the promising antitumor features of cis-dichlorotetrakis(dimethylsulfoxide)Ru(II) (cis- RuCl2(DMSO)4) and related complexes 122
Complessi di Rutenio con elevata attività antitumorale 122
Effects of isomeric aryldimethyl-triazenes on Lewis lung carcinoma growth and metastases in mice 122
Cis- and trans-dihalotetrakis(dimethylsulfoxide)Ruthenium(II) Complexes (RuX2(Me2SO)4; X = Cl, Br): Synthesis, Structure and Antitumor Activity 121
Recovery of lymphocyte CD4+:CD8+ ratio in patients treated with lysozyme 121
Synthesis and characterization of a diruthenium(II,III)-ketoprofen compound and study of the in vitro effects on CRC cells in comparison to the naproxen and ibuprofen derivatives 121
Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion 119
Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine 119
Metal-based antitumour drugs in the post genomic era 118
Tuning the hydrophobicity of ruthenium(ii)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy 118
Study of a potential drug delivery system based on carbon nanoparticles: Effects of fullerene derivatives in MCF7 mammary carcinoma cells 118
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound 117
Ruthenium drugs for cancer chemotherapy: an ongoing challenge to treat solid tumours 117
Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells. 116
Down-regulation of tumor gelatinase/inhibitor balance and preservation of tumor endothelium by an anti-metastatic ruthenium complex. 116
Mechanism of tumor inhibition by the metal complex trans-RuCl2(dimethylsulphoxide)4 116
Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. 115
Features and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice 115
Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A 114
Totale 14.631
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.324
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.324
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.766 0 0 0 0 0 0 0 0 0 0 1.206 560
2019/20206.106 317 254 277 1.048 402 829 636 813 535 346 501 148
2020/20214.262 431 164 385 634 274 505 200 385 202 494 137 451
2021/20223.269 103 257 189 471 49 259 137 118 390 347 203 746
2022/20233.931 430 436 288 491 447 748 9 356 478 24 159 65
2023/20241.662 164 134 113 113 224 92 246 512 29 35 0 0
Totale 30.301